NYSE:OGN

Organon & Co. (OGN) Stock Forecast, Price & News

$19.23

-0.31 (-1.59%)

(As of 09:45 AM ET)

Compare

Today's Range: $19.18
▼
$19.40
50-Day Range: $19.54
▼
$24.63
52-Week Range: $19.15
▼
$38.61

Volume: 132,286 shs
Average Volume: 2.10 million shs
Market Capitalization: $4.90 billion

P/E Ratio: 6.59
Dividend Yield: 5.82%
Price Target: $29.00

Organon & Co. MarketRank™ Forecast

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 48.4% Upside
$29.00 Price Target
Short Interest: Healthy
2.71% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.32
Upright™ Environmental Score
News Sentiment: 0.73
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 8.33%
From $4.20 to $4.55 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.11 out of 5 stars

Medical Sector

20th out of 1,009 stocks

Pharmaceutical Preparations Industry

7th out of 494 stocks

3.1

Analyst's Opinion

Consensus Rating
Organon & Co. has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $29.00, Organon & Co. has a forecasted upside of 48.4% from its current price of $19.54.
Amount of Analyst Coverage
Organon & Co. has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.71% of the float of Organon & Co. has been sold short.
Short Interest Ratio / Days to Cover
Organon & Co. has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Organon & Co. has recently increased by 11.65%, indicating that investor sentiment is decreasing significantly.

3.3

Dividend Strength

Dividend Leadership
Organon & Co. is a leading dividend payer. It pays a dividend yield of 5.73%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Organon & Co. does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Organon & Co. is 38.36%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Organon & Co. will have a dividend payout ratio of 24.62% next year. This indicates that Organon & Co. will be able to sustain or increase its dividend.

3.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Organon & Co. has received a 44.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Contraceptive implants", "Simvastatin", "Thiazide diuretics", "Losartan", "Ezetimibe", and "Rizatriptan" products. See details.
Environmental Sustainability
The Environmental Impact score for Organon & Co. is -2.32.

2.6

News and Social Media Coverage

News Sentiment
Organon & Co. has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Organon & Co. this week, compared to 2 articles on an average week.
Search Interest
30 people have searched for OGN on MarketBeat in the last 30 days. This is an increase of 58% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Organon & Co. to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Organon & Co. insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.03% of the stock of Organon & Co. is held by insiders.
Percentage Held by Institutions
75.74% of the stock of Organon & Co. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.8

Earnings and Valuation

Earnings Growth
Earnings for Organon & Co. are expected to grow by 8.33% in the coming year, from $4.20 to $4.55 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Organon & Co. is 6.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.48.
Price to Earnings Ratio vs. Sector
The P/E ratio of Organon & Co. is 6.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.87.
Price to Earnings Growth Ratio
Organon & Co. has a PEG Ratio of 0.85. PEG Ratios below 1 indicate that a company could be undervalued.

See Top Rated MarketRank™ Stocks Here

About Organon & Co. (NYSE:OGN) Stock

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Receive OGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter.

OGN Stock News Headlines

May 18, 2023 | finance.yahoo.com

ORGANON CANADA TO SUPPORT LE CHAÎNON BY FUNDING THE INITIAL CONSTRUCTION PHASE OF ITS MEDICAL CLINIC

May 8, 2023 | seekingalpha.com

Why Organon & Co. Is A Smart Investment

May 30, 2023 | Edge On The Street (Ad)

The Graphite Shortage Story You're Not Being Told

Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.

May 4, 2023 | benzinga.com

Organon shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS and sales results.

May 4, 2023 | finance.yahoo.com

Organon (OGN) Reports Q1 Earnings: What Key Metrics Have to Say

May 4, 2023 | seekingalpha.com

Organon Q1 Earnings Review: The Better Viatris, Still Not A Buy

May 4, 2023 | msn.com

Organon stock slumps ~10% as Q1 profit contracts amid flat revenue

May 4, 2023 | seekingalpha.com

Organon & Co. 2023 Q1 - Results - Earnings Call Presentation

May 30, 2023 | Edge On The Street (Ad)

The Graphite Shortage Story You're Not Being Told

May 4, 2023 | finance.yahoo.com

Organon Reports Results for the First Quarter Ended March 31, 2023

May 3, 2023 | msn.com

Organon's Earnings: A Preview

May 3, 2023 | americanbankingnews.com

Organon & Co. (OGN) Scheduled to Post Earnings on Thursday

April 20, 2023 | finance.yahoo.com

Organon To Report First Quarter and Host Conference Call on May 4, 2023

March 29, 2023 | bloomberg.com

Organon Seen Rallying on Birth-Control Demand in States Restricting Abortion

March 24, 2023 | seekingalpha.com

Organon: A Bitter Pill

March 17, 2023 | markets.businessinsider.com

Morgan Stanley Reaffirms Their Hold Rating on Organon (OGN)

March 16, 2023 | seekingalpha.com

Organon draws bullish views at Raymond James on Humira biosimilar launch

March 7, 2023 | finance.yahoo.com

Organon Launches "Her Plan is Her Power," a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist

March 3, 2023 | finance.yahoo.com

Organon Canada receives the Women in Governance (WiG) Parity Certification SME, further demonstrating its commitment to gender parity in the workplace

February 27, 2023 | finance.yahoo.com

Ahead of International Women's Day, Organon Canada Spotlights the Importance of Supporting Women's Equity While Highlighting the Cost of Not Investing in Their Health

February 19, 2023 | finance.yahoo.com

Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

February 18, 2023 | seekingalpha.com

Organon & Co (OGN) Q4 2022 Earnings Call Transcript

February 17, 2023 | finance.yahoo.com

Organon & Co. (OGN) Interactive Stock Chart - Yahoo Finance

February 16, 2023 | msn.com

Why Shares of Organon Fell 15% Thursday

February 16, 2023 | wsj.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Organon & Co. - OGN

February 16, 2023 | marketwatch.com

Organon Shares Drop 14% After 4Q Earnings Miss

February 16, 2023 | msn.com

Organon (OGN) Q4 Earnings and Revenues Miss Estimates

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive OGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter.

OGN Company Calendar

Ex-Dividend for 3/16 Dividend: 2/24/2023
Dividend Payable: 3/16/2023
Last Earnings: 5/04/2023
Ex-Dividend for 6/15 Dividend: 5/12/2023
Today: 5/30/2023
Dividend Payable: 6/15/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:OGN
CUSIP: N/A
CIK: 1821825
Web: www.organon.com
Phone: 551-430-6900
Fax: N/A
Employees: 10,000
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $29.00
High Stock Price Forecast: $34.00
Low Stock Price Forecast: $24.00
Forecasted Upside/Downside: +50.8%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.92
Trailing P/E Ratio: 6.59
Forward P/E Ratio: 4.58
P/E Growth: 0.85
Net Income: $917 million
Net Margins: 12.14%
Pretax Margin: 14.89%
Return on Equity: -119.00%
Return on Assets: 10.66%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.61
Quick Ratio: 1.13

Sales & Book Value

Annual Sales: $6.17 billion
Price / Sales: 0.79
Cash Flow: $5.79 per share
Price / Cash Flow: 3.32
Book Value: ($3.51) per share
Price / Book: -5.48

Miscellaneous

Outstanding Shares: 255,060,000
Free Float: 254,985,000
Market Cap: $4.90 billion
Optionable: Not Optionable
Beta: 0.77

Key Executives

Mr. Kevin Ali (Age 63)
CEO & Director
Comp: $3.08M

Mr. Matthew M. Walsh (Age 56)
Exec. VP & CFO
Comp: $1.57M

Ms. Susanne Gabriele Fiedler (Age 55)
Exec. VP & Chief Commercial Officer
Comp: $1.51M

Dr. Sandra Milligan J.D. (Age 59)
M.D., Exec. VP and Head of R&D
Comp: $1.21M

Ms. Rachel A. Stahler (Age 47)
Exec. VP & Chief Information Officer

Ms. Jennifer Halchak
VP of Investor Relations

Mr. Kirke Weaver
Gen. Counsel & Corp. Sec.

Mr. Aaron Falcione (Age 52)
Exec. VP & Chief HR Officer

Mr. Joseph T. Morrissey Jr. (Age 58)
Exec. VP and Head of Manufacturing & Supply

Mr. Vittorio Nisita (Age 55)
Exec. VP & Head of Global Bus. Services

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

OGN Stock - Frequently Asked Questions

Should I buy or sell Organon & Co. stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGN, but not buy additional shares or sell existing shares.
View OGN analyst ratings or view top-rated stocks.
What is Organon & Co.'s stock price forecast for 2023?: 4 brokers have issued 12 month target prices for Organon & Co.'s shares. Their OGN share price forecasts range from $24.00 to $34.00. On average, they anticipate the company's share price to reach $29.00 in the next twelve months. This suggests a possible upside of 50.8% from the stock's current price.
View analysts price targets for OGN or view top-rated stocks among Wall Street analysts.
How have OGN shares performed in 2023?: Organon & Co.'s stock was trading at $27.93 at the beginning of 2023. Since then, OGN shares have decreased by 31.1% and is now trading at $19.23.
View the best growth stocks for 2023 here.
When is Organon & Co.'s next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our OGN earnings forecast.
How were Organon & Co.'s earnings last quarter?: Organon & Co. (NYSE:OGN) released its earnings results on Thursday, May, 4th. The company reported $1.08 EPS for the quarter, missing the consensus estimate of $1.18 by $0.10. The firm had revenue of $1.54 billion for the quarter, compared to analysts' expectations of $1.54 billion. Organon & Co. had a net margin of 12.14% and a negative trailing twelve-month return on equity of 119.00%. The business's revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.65 earnings per share.
Read the conference call transcript.
How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?: Organon & Co. announced a quarterly dividend on Thursday, May 4th. Stockholders of record on Monday, May 15th will be given a dividend of $0.28 per share on Thursday, June 15th. This represents a $1.12 dividend on an annualized basis and a yield of 5.82%. The ex-dividend date is Friday, May 12th.
Read our dividend analysis for OGN.
What ETFs hold Organon & Co.'s stock?: ETFs with the largest weight of Organon & Co. (NYSE:OGN) stock in their portfolio include Timothy Plan Market Neutral ETF (TPMN), Invesco S&P Spin-Off ETF (CSD), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Emerge EMPWR Sustainable Dividend Equity ETF (EMCA), iShares U.S. Pharmaceuticals ETF (IHE), First Trust Nasdaq Pharmaceuticals ETF (FTXH) and ALPS Sector Dividend Dogs ETF (SDOG).
Is Organon & Co. a good dividend stock?: Organon & Co. (NYSE:OGN) pays an annual dividend of $1.12 per share and currently has a dividend yield of 5.73%. OGN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 38.36%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, OGN will have a dividend payout ratio of 24.62% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for OGN.

What guidance has Organon & Co. issued on next quarter's earnings?: Organon & Co. updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $6.15 billion-$6.45 billion, compared to the consensus revenue estimate of $6.29 billion.
What is Organon & Co.'s stock symbol?: Organon & Co. trades on the New York Stock Exchange (NYSE) under the ticker symbol "OGN."
Who are Organon & Co.'s major shareholders?: Organon & Co.'s stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.36%), Mawer Investment Management Ltd. (5.20%), State Street Corp (5.03%), Bank of New York Mellon Corp (2.14%), Geode Capital Management LLC (2.13%) and Sound Shore Management Inc. CT (1.31%).
View institutional ownership trends.
How do I buy shares of Organon & Co.?: Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Organon & Co.'s stock price today?: One share of OGN stock can currently be purchased for approximately $19.23.
How much money does Organon & Co. make?: Organon & Co. (NYSE:OGN) has a market capitalization of $4.90 billion and generates $6.17 billion in revenue each year. The company earns $917 million in net income (profit) each year or $2.92 on an earnings per share basis.
How many employees does Organon & Co. have?: The company employs 10,000 workers across the globe.
How can I contact Organon & Co.?: Organon & Co.'s mailing address is 2000 Galloping Hill Road, Kenilworth, New Jersey 07033. The official website for the company is www.organon.com. The company can be reached via phone at 551-430-6900 or via email at investor_relations@organon.com.

This page (NYSE:OGN) was last updated on 5/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Organon & Co. (OGN) Stock Forecast, Price & News

Organon & Co. MarketRank™ Forecast

Overall MarketRank™